This educational activity provides clinicians with an overview of current best practices and emerging clinical trial data related to the use of bispecific antibodies in the diagnosis, screening, and management of relapsed/refractory B-cell non-Hodgkin lymphomas (R/R B-NHLs), with a focus on safety considerations and adverse event management.

RELEASED DATE: January 06, 2026
EXPIRATION DATE: January 06, 2027

Non-Hodgkin’s Lymphoma accounts for about 4% of cancers in the US. It also affects the VA population and is majorly caused due to exposure to toxic substances. In this podcast, we will discuss the current treatments, adverse events and management of VA NHL patients. We will cover diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

RELEASED DATE: January 25, 2024
EXPIRATION DATE: January 25, 2025

This CME activity will provide hematologists and oncologists with practical, case-based insights into the management of patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma, with a special focus on follicular lymphoma (R/R FL). Expert faculty will review prognostic tools and clinical features, including early relapse, to guide risk stratification and inform treatment planning. The program will highlight the role of bispecific antibody therapies, with an emphasis on integrating clinical trial data into personalized care strategies. Special attention will be given to proactive recognition, grading, and management of toxicities, particularly cytokine release syndrome, as well as best practices in infection prophylaxis and monitoring. Through didactic discussion, illustrative case study, and whiteboard animation, learners will gain strategies to optimize outcomes and safely implement bispecific therapies for patients with R/R FL.

RELEASED DATE: August 29, 2025
EXPIRATION DATE: August 29, 2026

These podcasts are designed to help healthcare professionals assess the relationship between checkpoint inhibition and immunopathology in advanced melanoma, update them on the latest clinical data with anti-LAG3 antibody combinations in advanced melanoma, and provide strategies to optimize the safety of combination immunotherapy approaches in advanced melanoma. Additionally, healthcare professionals will be able to understand the importance of patient advocacy as we converse with a patient about their cancer diagnosis and treatment.

RELEASED DATE: April 21, 2023
EXPIRATION DATE: April 21, 2024

This program will dive into the latest advances in the management of non-melanoma skin cancers (NMSCs), including new data presented at ESMO. Through real-world clinical cases, faculty will guide participants in applying emerging evidence—particularly regarding neoadjuvant and adjuvant immune checkpoint inhibitors—to personalize treatment based on patient- and disease-specific risk factors. The session will also emphasize shared decision-making and multidisciplinary care to support coordinated, patient-centered treatment planning for individuals with advanced NMSCs.

RELEASED DATE: November 21, 2025
EXPIRATION DATE: November 21, 2026

Tuesday, June 9, 2026

1:00 p.m. – 2:00 p.m. ET

Please note this TeleECHO program is 1:00 p.m. Eastern, 12:00 p.m. Central, 11:00 a.m. Mountain and 10:00 a.m. Pacific.

Tuesday, July 14, 2026

12:00 p.m. – 1:00 p.m. ET

Please note this TeleECHO program is 12:00 p.m. Eastern, 11:00 a.m. Central, 10:00 a.m. Mountain and 9:00 a.m. Pacific.

Tuesday, June 16, 2026

2:00 p.m. – 3:00 p.m. ET

Please note this TeleECHO program is 2:00 p.m. Eastern, 1:00 p.m. Central, 12:00 p.m. Mountain and 11:00 a.m. Pacific.

Wednesday, July 1, 2026

1:00 p.m. – 2:00 p.m. ET

Please note this TeleECHO program is 1:00 p.m. Eastern, 12:00 p.m. Central, 11:00 a.m. Mountain and 10:00 a.m. Pacific.

Friday, June 26, 2026

1:00 p.m. – 2:00 p.m ET

Please note this TeleECHO program is 1:00 p.m. Eastern, 12:00 p.m. Central, 11:00 a.m. Mountain and 10:00 a.m. Pacific.